Synthetic-user startup Simile raises $200M at $2B valuation 5 months after $100M Series A
Simile, a synthetic-user startup founded by Stanford PhD Joon Sung Park, raised a $200M Series B at a $2B valuation just five months after a $100M Series A led by Index Ventures.
Intelligence analysis by Llama
Simile, founded by Stanford PhD Joon Sung Park of 'Smallville' AI-agent fame, doubled down on the synthetic-user thesis with a $200M Series B at a $2B valuation only five months after its $100M Series A. Greenoaks led the round.
A company called Simile makes pretend people on computers so other companies can ask them questions instead of asking real people. Investors think this is so valuable that they gave the company $200 million and decided it was worth $2 billion, all just five months after their last big investment.
Analysis
From Smallville to Series B
The round is rooted in unusual academic provenance. Simile was founded by Joon Sung Park, a Stanford PhD whose dissertation research produced "Smallville," a project in which AI agents lived out simulated days — attending parties, forming relationships, and gossiping. The Series B lifts Park's work from a research curiosity into commercial reality, with synthetic users pitched to companies that need fast, low-cost consumer insight without running traditional surveys or focus groups. Index, which led the Series A only five months ago, doubled down in the new round alongside Bain Capital Ventures, A*, Hanabi, Factory, Definition, and CVS Health Ventures — the corporate venture arm of one of Simile's marquee customers.
A 20x markup, five months apart
The pace of the fundraise is itself the headline of the deal. Five months between a $100 million Series A and a $200 million Series B at a $2 billion valuation implies an aggressive markup even by current AI-unicorn standards, and it places Simile among a recent wave of synthetic-research companies pulling in nine-figure rounds. Fellow synthetic-user startup Aaru, for example, raised a Series A in December at a $1 billion headline valuation, suggesting Simile is not alone in drawing institutional appetite for AI-driven market research, per the article. The B round was led by Greenoaks, a firm that has written large checks into AI infrastructure and applied AI companies, with participation from investors who were already on the cap table at the Series A.
Replacing humans — or augmenting them?
The article's framing tempers the enthusiasm. The startup's stated mission of simulating "all eight billion people on earth, accurately and honestly" is, as the publication puts it, "preposterous" — because the whole reason to do market research is that humans are unpredictable and guided by both emotion and reason. A more realistic comparison, the article suggests, is to "vibe coding for product mock-ups": synthetic respondents as rapid-iteration tools for early-stage product and marketing work, rather than wholesale replacements for human panels. Even with CVS among its marquee customers, the longer-term question is whether enterprises will trust simulated users enough to redirect real research budgets away from live audiences, and whether brand-standards teams and regulators will accept the approach for high-stakes decisions.
Key points
- Simile raised a $200M Series B at a $2B valuation, led by Greenoaks, just five months after a $100M Series A led by Index Ventures.
- The startup was founded by Stanford PhD Joon Sung Park, whose dissertation project 'Smallville' featured AI agents living simulated human lives.
- CVS Health Ventures participated in the round and CVS is identified as a marquee Simile customer.
- Simile offers simulated users for marketing and product research, pitched as a faster alternative to traditional consumer panels.
- Other synthetic-user startups, including Aaru, have also raised large rounds recently, indicating a budding category of investor interest.
The depth of the investor syndicate — Greenoaks leading with Index, Bain Capital Ventures, and the corporate venture arm of CVS Health Ventures all participating — suggests meaningful conviction in synthetic-research economics, per the article's framing of the round. If Simile can deliver faster, cheaper consumer insight for routine marketing and product decisions, the category could pull real research budgets from traditional panels at scale.
The article explicitly calls the mission of simulating all eight billion humans "preposterous," and warns that human unpredictability is precisely why market research exists. If simulated respondents introduce systematic bias, enterprises like CVS could find their product and brand decisions undermined, inviting regulatory scrutiny and a credibility backlash that would hit the entire synthetic-research category.
